• Aging-focused therapies offer a potentially broad market for drugmakers, though most development programs remain early-stage.
• The global population over 60 is projected to double to 2.1 billion by 2050, increasing healthcare demand.
• GLP-1 research activity involving dementia and Alzheimer's grew more than 17-fold from 2010 to 2025.
• Life Biosciences' ER-100 became the first partial epigenetic reprogramming therapy to enter human trials in June 2026, targeting optic neuropathies.
• Clinical setbacks highlight development risks: Novo Nordisk's Phase 3 EVOKE and EVOKE+ trials found oral semaglutide did not significantly slow Alzheimer's progression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definitive Healthcare Corp. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.